Selected price target: $20 per share, roughly 54% above recent trading levels near $13. Strongest bullish factor: DURAVYU, the company's lead sustained-delivery eye treatment, is advancing through pivotal Phase 3 trials, with wet AMD data anticipated beginning in August 2026.

Selected stock price target: $40, which sits just above LEGN’s 52-week high of $38.35 and implies nearly double the recent price near $20.60. Strongest bullish factors: accelerating Carvykti sales, the first quarter of company-wide profitability, and promising early in vivo CAR-T data.

GFUZ is trading down -9.03% during Wednesday's regular session at $8.36, versus the prior close of $9.19. The decline follows Tuesday's +5.39% gain, putting shares in a sharp pullback amid continued post-SPAC volatility.

TOP Financial Group shares are down -8.55% during regular market hours on Aug. 12, slipping to $11.02 from the prior close of $12.05. The pullback follows a sharp post-consolidation rally after the company's 1-for-5 share consolidation took effect on Aug. 3.

WeRide shares are down -9.32% during regular U.S. trading, last near $5.74 after closing at $6.33 on Tuesday. The drop follows Q2 2026 results released before the open: revenue jumped +92% y/y to $34.15 million, but continued losses weighed on sentiment.

EYE shares fell -7.07% to $20.50 during regular trading Wednesday, erasing a roughly +2% premarket gain after its Q2 report. Q2 adjusted EPS of $0.25 beat the $0.18 consensus, but revenue of $498.8M missed estimates and adjusted comparable-store sales rose only +2.2%.

OBX traded down -15.25% to $27.88 during regular hours Wednesday, following a prior-session close at $32.90 (-6.00%). The decline extends a volatile post-debut stretch after the Aug 4 reverse merger with Galera and the $350 million private placement.

HPK traded down -10.29% to $7.41 during Wednesday’s regular session, versus a prior close of $8.26. The decline accelerated in afternoon trading after US-Iran peace-deal headlines sent WTI crude down more than 5% toward $80.61, hitting high-beta shale E&P names hardest.

MAAS is down -19.34% to $16.85 in regular trading on Aug. 12, versus a previous close of $20.89. The move built on premarket weakness and deepened through the session; by midday shares were already off -16.85% to $17.37.

Selected price target: $2.00 per share, roughly 160% above Inovio's recent trading level near $0.77. Strongest bullish factor: The FDA is reviewing Inovio's lead DNA medicine candidate, INO-3107, with a PDUFA target action date of October 30, 2026.

Both GLD and IAU provide direct exposure to physical gold bullion and track the LBMA Gold Price, resulting in nearly identical underlying performance profiles. Structural differences center on expense ratios, with GLD at 0.40% and IAU at 0.25%, creating a persistent cost advantage for long-term holders of IAU .

Inovio Pharmaceuticals (NASDAQ: INO) is scheduled to report second-quarter 2026 results after the U.S. market close on August 12, 2026, followed by a conference call at 4:30 p.m. Eastern Time. The consensus estimate calls for a net loss of $0.24 per share, narrower than the $0.61 loss reported in the prior-year quarter.

INO shares fell approximately 33.5% from a closing price of $1.16 on July 13, 2026, to an intraday price near $0.77 on August 12, 2026. The sharpest sell-off followed INOVIO's late-July pricing of a $20 million public offering of common stock and warrants, which triggered immediate dilution concerns.

Multiple late-stage oncology readouts, including five-year Phase 2 melanoma data and Phase 3 adjuvant melanoma results for intismeran, are expected in 2026 and could shape sentiment around the mRNA platform's expansion into cancer therapies. Potential regulatory approvals for mNEXSPIKE in select markets, flu vaccine, and flu + COVID-19 combination candidates position the company for portfolio diversification beyond its established COVID-19 franchise.

Selected price target: $7.00 per share, the most widely cited lower-bound analyst target and a round-number level sitting just above the stock's 52-week high of $6.55. Starting point: SANA closed the most recent regular session near $3.79, meaning a move to $7 would require roughly 85% upside.

Selected price target: $60, approximately 47% above the recent $40.91 close and essentially in line with the consensus analyst price target of about $60. Strongest bullish factor: A late-stage pipeline led by DT120 in depression and anxiety, supported by U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for generalized anxiety disorder (GAD).

The selected price target is $7 , roughly 81% above the latest close of $3.87 and about 35% above the 52-week high of $5.17. Wall Street support is a key bullish factor: the low end of current analyst price targets clusters near $6 to $7, with consensus estimates well above that level.

BAC traded near $64.37 in mid-August 2026, roughly 8.2% above the July 13, 2026 close of $59.50, extending a steady 30-day advance. Second-quarter results released July 14 beat expectations, with EPS of $1.21, revenue of $31.6 billion, and net income up 27% year over year.

SEALSQ Corp (LAES) operates as a subsidiary of WISeKey International Holding AG (WKEY), focusing on semiconductors and post-quantum security solutions. Both companies target cybersecurity, IoT, and quantum-resistant technologies, with recent press releases highlighting partnerships, executive appointments, and product developments in the past month.

As of the August 12, 2026 intraday session, LAES traded near $2.60, down about 4% from the July 13, 2026 close of $2.71 over the trailing 30 days. The modest move keeps the stock in consolidation below its 50-day and 200-day moving averages, within a 52-week range of $1.99 to $8.71.